Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Donor Natural Killer Cell Therapy
- Development stage
- Unknown
- Lead developer
- Fred Hutchinson Cancer Center
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Donor Natural Killer Cell Therapy is an investigational adoptive cellular immunotherapy developed by the Fred Hutchinson Cancer Center for the treatment of various hematologic malignancies. The therapy consists of a single, purified infusion of natural killer (NK) cells derived from an HLA-haploidentical donor, typically the same donor used for a preceding hematopoietic cell transplantation (HCT). Administered on day +7 following nonmyeloablative HCT, these NK cells are intended to provide a pre-emptive graft-versus-tumor (GVT) effect to eliminate residual cancer cells and prevent disease relapse. Because NK cells do not typically cause graft-versus-host disease (GVHD) in the same manner as T cells, this approach aims to enhance the anti-tumor efficacy of the transplant without increasing the risk of severe immune-mediated complications. It is currently being studied in Phase I/II trials for conditions including acute myeloid leukemia, acute lymphoblastic leukemia, and several types of lymphoma and myeloma.
- Other names
- Prophylactic Donor NK Cell InfusionDonor Natural Killer CellsNK Cell DLINatural Killer Cell Therapy (Fred Hutchinson Cancer Center)
Beyond the preview
Go deeper on Donor Natural Killer Cell Therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Donor Natural Killer Cell Therapy.